Tradename: OMISIRGE
Proper Name: omidubicel-onlv
Indication: Indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
Approval Date: 04/17/2023
Manufacturer: : Gamida Cell Ltd.
More: https://www.fda.gov/vaccines-blood-biologics/omisirge